Short answer
Lucid Diagnostics Inc. (LUCD) filed an 8-K current report with the SEC on April 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). $18 million gross proceeds from sale of 18 million common shares.
Lucid Diagnostics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $18 million gross proceeds from sale of 18 million common shares
- $1.00 public price, with $0.94 proceeds per share after $0.06 underwriting discount
- Approximately 18 million new shares, creating material dilution for existing shareholders
- Net proceeds reduced by underwriting discount, offering expenses, and up to $75,000 underwriter expense reimbursement
- Closing expected April 24, 2026, subject to customary conditions
Item 7.01 · Regulation FD Disclosure
- Boilerplate Regulation FD disclaimer only
- No substantive business, financial, or operational disclosure in the provided excerpt
Item EX-99.1 · Exhibit EX-99.1
- $18M underwritten offering of 18,000,000 shares priced at $1.00 per share
- $15M anchored by a fundamental institutional investor, with support from an existing shareholder
- Net proceeds designated for working capital and general corporate purposes
- Expected closing April 24, 2026, subject to customary conditions
- Equity issuance provides liquidity but dilutes existing shareholders and signals ongoing funding needs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lucid Diagnostics Inc. 8-K filings
Get the next LUCD 8-K as it lands
Follow LUCD for push alerts, or ask the research agent what this filing means.